DK2707393T3 - Fusionsproteiner og kombinationsvacciner omfattende haemoph-ilus influenzae-protein e og pilin a - Google Patents

Fusionsproteiner og kombinationsvacciner omfattende haemoph-ilus influenzae-protein e og pilin a

Info

Publication number
DK2707393T3
DK2707393T3 DK12771540.7T DK12771540T DK2707393T3 DK 2707393 T3 DK2707393 T3 DK 2707393T3 DK 12771540 T DK12771540 T DK 12771540T DK 2707393 T3 DK2707393 T3 DK 2707393T3
Authority
DK
Denmark
Prior art keywords
pilin
fusion proteins
haemoph
combination vaccines
influenzae protein
Prior art date
Application number
DK12771540.7T
Other languages
English (en)
Inventor
Normand Blais
Steve Labbe
Jan Poolman
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47008755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2707393(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Application granted granted Critical
Publication of DK2707393T3 publication Critical patent/DK2707393T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK12771540.7T 2011-04-13 2012-04-12 Fusionsproteiner og kombinationsvacciner omfattende haemoph-ilus influenzae-protein e og pilin a DK2707393T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161474779P 2011-04-13 2011-04-13
US201161534012P 2011-09-13 2011-09-13
PCT/CA2012/050236 WO2012139225A1 (en) 2011-04-13 2012-04-12 Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a

Publications (1)

Publication Number Publication Date
DK2707393T3 true DK2707393T3 (da) 2018-01-29

Family

ID=47008755

Family Applications (2)

Application Number Title Priority Date Filing Date
DK12771540.7T DK2707393T3 (da) 2011-04-13 2012-04-12 Fusionsproteiner og kombinationsvacciner omfattende haemoph-ilus influenzae-protein e og pilin a
DK17201766.7T DK3321287T3 (da) 2011-04-13 2012-04-12 Fusionsproteiner og kombinationsvacciner

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK17201766.7T DK3321287T3 (da) 2011-04-13 2012-04-12 Fusionsproteiner og kombinationsvacciner

Country Status (34)

Country Link
US (7) US8945577B2 (da)
EP (2) EP3321287B1 (da)
JP (1) JP6196963B2 (da)
KR (1) KR101999673B1 (da)
CN (3) CN107522788A (da)
AR (1) AR086078A1 (da)
AU (1) AU2012243412C1 (da)
BR (1) BR112013026175B1 (da)
CA (1) CA2830786C (da)
CL (1) CL2013002937A1 (da)
CO (1) CO6781540A2 (da)
CR (1) CR20130529A (da)
CY (2) CY1120319T1 (da)
DK (2) DK2707393T3 (da)
DO (1) DOP2013000235A (da)
EA (1) EA031580B1 (da)
ES (2) ES2776369T3 (da)
HR (2) HRP20180216T1 (da)
HU (2) HUE048848T2 (da)
IL (2) IL271862B (da)
LT (2) LT3321287T (da)
MA (1) MA35110B1 (da)
ME (1) ME02995B (da)
MX (1) MX350013B (da)
PE (1) PE20140986A1 (da)
PL (2) PL3321287T3 (da)
PT (2) PT3321287T (da)
RS (1) RS56903B1 (da)
SG (2) SG193906A1 (da)
SI (2) SI2707393T1 (da)
TW (1) TW201302779A (da)
UY (1) UY34017A (da)
WO (1) WO2012139225A1 (da)
ZA (1) ZA201307118B (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
GB201218660D0 (en) 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
BR112015008418A2 (pt) * 2012-10-17 2017-07-04 Glaxosmithkline Biologicals Sa uso de uma composição imunogênica, composição imunogênica, e, métodos para intensificar atividade opsônica mediada por anticorpo contra um sorotipo alvejado de streptococcus pneumoniae em um indivíduo e para imunizar um hospedeiro humano contra doenças causadas por infecção por streptococcus pneumoniae
ES2911086T3 (es) 2013-09-30 2022-05-17 Iaf Science Holdings Ltd Producto masticable que comprende un agente activo y procedimiento para prepararlo
TW201620927A (zh) 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
US10648966B2 (en) * 2015-01-16 2020-05-12 University Of Kentucky Research Foundation Lipid bilayer-integrated SPP1 connector protein nanopore and SPP1 connector protein variants for use as lipid bilayer-integrated nanopore
CN105175549B (zh) * 2015-09-30 2019-08-16 康希诺生物股份公司 一种流感嗜血杆菌融合蛋白及其构建方法与应用
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
BR112019020209A2 (pt) * 2017-03-31 2020-06-02 Glaxosmithkline Intellectual Property Development Limited Composição imunogênica, uso de uma composição imunogênica, método de tratamento ou prevenção de uma recorrência de uma exacerbação aguda de doença pulmonar obstrutiva crônica, e, terapia de combinação.
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
IE87413B1 (en) 2017-05-30 2023-07-19 Glaxosmithkline Biologicals Sa Novel methods for manufacturing an adjuvant
US11723966B2 (en) 2017-08-14 2023-08-15 Glaxosmithkline Biologicals Sa Methods of boosting immune responses
CN107602697B (zh) * 2017-08-29 2020-05-05 杭州医学院 一种治疗流感嗜血杆菌引起鼻窦炎的血清及该血清的应用
CA3083078A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
WO2019243307A1 (en) * 2018-06-19 2019-12-26 Glaxosmithkline Biologicals Sa Immunogenic composition
BR112021000965A2 (pt) 2018-08-07 2021-04-27 Glaxosmithkline Biologicals S.A. processos e vacinas
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
CN110540598B (zh) * 2018-12-20 2021-04-30 湖北工业大学 基于流感嗜血杆菌表面蛋白抗体的流感嗜血杆菌Elisa检测试剂盒及制备方法
CN110540597B (zh) * 2018-12-20 2021-04-30 湖北工业大学 基于流感嗜血杆菌表面蛋白的乳胶微球免疫层析试纸的制备方法
US20220143168A1 (en) 2019-02-27 2022-05-12 Evaxion Biotech A/S Vaccines targeting H. influenzae
US20220221455A1 (en) 2019-04-18 2022-07-14 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
CA3142300A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
BR112021026565A2 (pt) 2019-08-05 2022-05-03 Glaxosmithkline Biologicals Sa Composição imunogênica
CN114245746A (zh) 2019-08-05 2022-03-25 葛兰素史克生物有限公司 用于制备包含蛋白d多肽的组合物的方法
WO2022175423A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Biologicals Sa Immunogenic composition, use and methods
KR20220142219A (ko) * 2021-04-14 2022-10-21 한국생명공학연구원 장내 미생물에서 단백질 분비를 유도하는 신호서열
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE454403B (sv) 1984-05-30 1988-05-02 Alfa Laval Agri Int Anvendning av ett cellyteprotein med fibronektin-, fibrinogen-, kollagen-, och/eller lamininbindande egenskaper vid framstellning av sarbehandlingsmedel
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DK0606921T3 (da) 1989-03-09 2000-09-04 American Cyanamid Co Fremgangsmåde til isolering af Haemophilus influenzae protein E
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
JP3755890B2 (ja) 1992-06-25 2006-03-15 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） アジュバント含有ワクチン組成物
EP0812593B8 (en) 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
SI1082965T1 (sl) 1995-06-23 2009-08-31 Glaxosmithkline Biolog Sa Sestavek cepiva, ki vsebuje antigen konjugata polisaharida, adsorbiranega na aluminijevem fosfatu
KR100615109B1 (ko) 1996-12-20 2006-08-22 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 모렉셀라 카타르할리스의 ｕｓｐａ1, ｕｓｐａ2 항원
DE60132471T2 (de) 2000-09-26 2009-01-15 Idera Pharmaceuticals, Inc., Cambridge Modulation der immunostimulatorischen aktivität von immunostimulierenden oligonukleotidanaloga durch positionelle chemische veränderungen
PT2088197T (pt) 2000-10-02 2016-08-01 Id Biomedical Corp Quebec Antigénios de haemophilus influenzae e fragmentos de adn correspondentes
US6942802B2 (en) 2001-04-13 2005-09-13 Wyeth Holdings Corporation Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
GB0222764D0 (en) 2002-10-02 2002-11-06 Univ Bristol Therapeutic peptide
US7049076B2 (en) 2003-07-09 2006-05-23 Sentigen Biosciences, Inc. Method for assaying protein—protein interaction
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
PE20061441A1 (es) * 2005-05-12 2007-01-18 Novartis Ag Genes y proteinas novedosos de brachyspira hyodysenteriae y uso de los mismos para diagnostico y terapia
PL1902131T3 (pl) * 2005-07-08 2010-05-31 Univ Zuerich Prezentacja fagowa z zastosowaniem kotranslacyjnej translokacji polipeptydów fuzyjnych
CA2613970C (en) * 2005-07-08 2015-12-08 Children's Hospital, Inc. Chimeric vaccine for haemophilus influenzae-induced disease
EP3305807A1 (en) 2005-08-10 2018-04-11 Arne Forsgren AB Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
CN101374859B (zh) * 2006-01-17 2014-11-26 阿恩·福斯格伦 新的表面外露流感嗜血菌蛋白质(蛋白质E；pE)
GB2444903A (en) * 2006-12-21 2008-06-25 Secr Defence Live Francisella vaccine, inactivated at gene FTT1564
KR20110038047A (ko) 2008-06-20 2011-04-13 고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 산화 ＬＤＬ／β２ＧＰＩ복합체에 대한 항체 및 그 용도
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗

Also Published As

Publication number Publication date
BR112013026175B1 (pt) 2020-05-12
CA2830786C (en) 2021-10-26
US20170029472A1 (en) 2017-02-02
HUE048848T2 (hu) 2020-08-28
CA2830786A1 (en) 2012-10-18
EA031580B1 (ru) 2019-01-31
PT3321287T (pt) 2020-05-22
EP3321287B1 (en) 2020-02-26
SG10201602549WA (en) 2016-05-30
US8945577B2 (en) 2015-02-03
EP2707393B1 (en) 2017-12-20
IL228344B (en) 2020-01-30
CN107522788A (zh) 2017-12-29
ZA201307118B (en) 2022-03-30
CR20130529A (es) 2014-03-05
ES2776369T3 (es) 2020-07-30
RS56903B1 (sr) 2018-05-31
SI3321287T1 (sl) 2020-07-31
SI2707393T1 (en) 2018-03-30
AU2012243412B2 (en) 2015-05-14
LT2707393T (lt) 2018-03-12
JP2014512365A (ja) 2014-05-22
US10023616B2 (en) 2018-07-17
CY1120319T1 (el) 2019-07-10
HUE036983T2 (hu) 2018-08-28
PL3321287T3 (pl) 2020-07-27
DOP2013000235A (es) 2014-03-16
PE20140986A1 (es) 2014-08-20
CN107383201A (zh) 2017-11-24
UY34017A (es) 2012-11-30
PL2707393T3 (pl) 2018-05-30
EP2707393A1 (en) 2014-03-19
LT3321287T (lt) 2020-06-10
US20160250313A1 (en) 2016-09-01
MX2013011939A (es) 2014-03-27
NZ615328A (en) 2015-10-30
US9409957B2 (en) 2016-08-09
HRP20180216T1 (hr) 2018-03-09
ES2658512T3 (es) 2018-03-12
WO2012139225A1 (en) 2012-10-18
EP2707393A4 (en) 2014-11-05
CO6781540A2 (es) 2013-10-31
HRP20200466T1 (hr) 2020-06-26
US20180222946A1 (en) 2018-08-09
IL271862A (en) 2020-02-27
PT2707393T (pt) 2018-02-09
DK3321287T3 (da) 2020-05-04
CY1122824T1 (el) 2021-05-05
TW201302779A (zh) 2013-01-16
MX350013B (es) 2017-08-23
KR101999673B1 (ko) 2019-07-12
EA201391240A1 (ru) 2014-04-30
EP3321287A1 (en) 2018-05-16
CN103476799A (zh) 2013-12-25
US9296794B2 (en) 2016-03-29
US20150166613A1 (en) 2015-06-18
AR086078A1 (es) 2013-11-20
KR20140026483A (ko) 2014-03-05
IL228344A0 (en) 2013-12-31
US20150175670A1 (en) 2015-06-25
AU2012243412A1 (en) 2013-04-18
US10214569B2 (en) 2019-02-26
CL2013002937A1 (es) 2014-07-25
IL271862B (en) 2022-07-01
ME02995B (me) 2018-10-20
US10730917B2 (en) 2020-08-04
US11198707B2 (en) 2021-12-14
JP6196963B2 (ja) 2017-09-13
BR112013026175A2 (pt) 2016-11-29
US20200331972A1 (en) 2020-10-22
US20140056934A1 (en) 2014-02-27
AU2012243412C1 (en) 2015-12-10
SG193906A1 (en) 2013-11-29
MA35110B1 (fr) 2014-05-02

Similar Documents

Publication Publication Date Title
DK2707393T3 (da) Fusionsproteiner og kombinationsvacciner omfattende haemoph-ilus influenzae-protein e og pilin a
EA201391597A1 (ru) Толерогенные синтетические наноносители, уменьшающие иммунный ответ на терапевтические белки
RU2017104529A (ru) Композиции neisseria meningitidis и способы их применения
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
EP3988115A3 (en) Rsv f protein compositions and methods for making same
EP3082797A4 (en) Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
WO2014176373A3 (en) Interleukin-10 compositions and uses thereof
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
WO2008134643A3 (en) Trypanosoma antigens, vaccine compositions, and related methods
WO2014136064A3 (en) Immunogenic fusion polypeptides
EA201590490A1 (ru) ИММУНОГЕННАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ОДИН ИЛИ БОЛЕЕ КОНЪЮГАТОВ КАПСУЛЬНЫХ САХАРИДОВ STREPTOCOCCUS PNEUMONIAE И БЕЛКОВЫЙ КОМПОНЕНТ, ВКЛЮЧАЮЩИЙ БЕЛОК Е И/ИЛИ PilA ИЗ HAEMOPHILIUS INFLUENZAE
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
EA201171043A1 (ru) Композиции и способы длительной терапии с применением аминопиридинов
IL232867B (en) Amyloid-binding polypeptide and chimeric protein containing it, pharmaceutical preparations containing the polypeptide or chimeric protein, methods for their preparation and uses
SMT201600147B (it) Metodi per migliorare l'espressione di proteine ricombinanti
GB201017519D0 (en) Vaccines
FR2932681B1 (fr) Peptides immunogenes issus de la proteine midkine comme vaccin anticancereux
WO2010150242A3 (en) Immunogenic streptococcus pneumoniae peptides and peptide-multimers
NZ596501A (en) Casb7439 constructs
CL2012002378A1 (es) Metodo para producir proteinas de interferon tipo 1 recombinantes solubles sin desnaturalizacion.
WO2012174455A3 (en) Group a streptococcus multivalent vaccine
WO2011067758A3 (en) Immunogenic fragments and multimers from streptococcus pneumoniae proteins
WO2011100508A3 (en) Methods and compositions related to glycoprotein-immunoglobulin fusions
WO2009131698A3 (en) PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE (NaGlu) AND USES THEREOF
EP4227685A3 (en) Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus